MCID: BRS049
MIFTS: 51

Breast Carcinoma in Situ malady

Genetic diseases, Cancer diseases, Rare diseases, Reproductive diseases categories
Download this MalaCard

Summaries for Breast Carcinoma in Situ

About this section


Fully expand this MalaCard
MalaCards based summary: Breast Carcinoma in Situ, also known as non-infiltrating carcinoma of breast, is related to breast cancer and ductal carcinoma in situ. An important gene associated with Breast Carcinoma in Situ is VEGFC (vascular endothelial growth factor C), and among its related pathways are Fanconi anemia pathway and Homologous Recombination Repair. The compounds topotecan and crcs have been mentioned in the context of this disorder. Affiliated tissues include breast and testes, and related mouse phenotypes are no phenotypic analysis and limbs/digits/tail.

Aliases & Classifications for Breast Carcinoma in Situ

About this section

Breast Carcinoma in Situ, Aliases & Descriptions:

Name: Breast Carcinoma in Situ 8
Non-Infiltrating Carcinoma of Breast 8 62
 
Carcinoma in Situ of Breast 8 62


Classifications:



External Ids:

Disease Ontology8 DOID:8791
NCIt39 C3641
ICD9CM27 233.0
ICD1025 D05

Related Diseases for Breast Carcinoma in Situ

About this section

Diseases in the Breast Cancer family:

Inflammatory Breast Carcinoma Breast Benign Neoplasm
breast carcinoma in situ Familial Breast Cancer
Chek2-Related Susceptibility to Breast Cancer Bard1-Related Susceptibility to Breast Cancer
Brip1-Related Breast Cancer Breast Cancer, Type 3
Breast Cancer, Early-Onset

Diseases related to Breast Carcinoma in Situ via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 84)
idRelated DiseaseScoreTop Affiliating Genes
1breast cancer31.0BRCA1, BRCA2
2ductal carcinoma in situ29.9CDH1, ERBB2, BRCA1, TP53, BRCA2
3ovarian cancer28.9VEGFC, TP53, BRCA2, BRCA1, MET, ERBB2
4breast-ovarian cancer, familial, 110.5BRCA2
5chordoma10.5KRT19
6nodular goiter10.3KRT19, VEGFC
7follicular thyroid carcinoma10.3VEGFC, KRT19
8papillary thyroid carcinoma10.3MET, VEGFC
9poland syndrome10.2
10lobular neoplasia10.2
11brca1 and brca2 hereditary breast and ovarian cancer10.2BRCA2, BRCA1
12cystadenoma10.2VEGFC, BRCA1
13fallopian tube cancer10.2BRCA1, BRCA2
14peritoneal carcinoma10.2BRCA1, BRCA2
15bilateral breast cancer10.2BRCA1, BRCA2
16lynch syndrome10.2BRCA2, BRCA1
17familial colorectal cancer10.2BRCA2, BRCA1
18tongue cancer10.2CDH1, VEGFC
19dysgerminoma10.2BRCA2, BRCA1
20microinvasive gastric cancer10.2VEGFC, CDH1
21cowden disease10.2BRCA1, BRCA2
22female breast carcinoma10.2
23hypoxia10.2
24gynecomastia10.2BRCA1, BRCA2
25uveal melanoma10.2MET, VEGFC
26laryngeal benign neoplasm10.2TP53, VEGFC
27bloom syndrome10.2BRCA1, BRCA2
28tongue squamous cell carcinoma10.2KRT19, CDH1
29neuroendocrine carcinoma10.1KRT19, CDH1
30nasopharynx carcinoma10.1TP53, CDH1
31aplastic anemia10.1BRCA2, BRCA1
32biliary tract neoplasm10.1ERBB2, MET
33renal clear cell carcinoma10.1CDH1, MET
34lung benign neoplasm10.1TP53, MET, KRT19
35breast fibroadenoma10.1ERBB2, VEGFC
36cervical cancer10.1VEGFC, TP53, KRT19
37synovial sarcoma10.1KRT19, MET, CDH1
38follicular adenoma10.1CDH1, KRT19, MET
39fanconi's anemia10.0BRCA1, BRCA2
40malignant mixed mullerian tumor10.0ERBB2, TP53
41esophageal cancer10.0VEGFC, TP53
42li-fraumeni syndrome10.0BRCA1, BRCA2, TP53
43bladder transitional cell carcinoma10.0TP53, VEGFC, CDH1
44xeroderma pigmentosum10.0TP53, BRCA1
45malignant mesothelioma10.0MET, KRT19
46ataxia telangiectasia10.0BRCA1, BRCA2, TP53
47thyroid cancer, anaplastic10.0CDH1, MET, TP53
48sarcoma10.0MET, BRCA2, TP53
49tubular adenocarcinoma10.0ERBB2, CDH1
50thyroid hurthle cell carcinoma10.0TP53, VEGFC, KRT19, MET

Graphical network of the top 20 diseases related to Breast Carcinoma in Situ:



Diseases related to breast carcinoma in situ

Symptoms for Breast Carcinoma in Situ

About this section

Drugs & Therapeutics for Breast Carcinoma in Situ

About this section

Drug clinical trials:

Search ClinicalTrials for Breast Carcinoma in Situ

Search NIH Clinical Center for Breast Carcinoma in Situ

Genetic Tests for Breast Carcinoma in Situ

About this section

Anatomical Context for Breast Carcinoma in Situ

About this section

MalaCards organs/tissues related to Breast Carcinoma in Situ:

32
Breast, Testes

Animal Models for Breast Carcinoma in Situ or affiliated genes

About this section

MGI Mouse Phenotypes related to Breast Carcinoma in Situ:

36 (show all 19)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00030128.4CDH1, KRT19, MET, TP53
2MP:00053718.4TP53, BRCA2, BRCA1, MET, ERBB2
3MP:00053888.3TP53, BRCA1, MET, ERBB2
4MP:00053868.2ERBB2, MET, BRCA1, BRCA2, TP53
5MP:00053908.1TP53, BRCA2, BRCA1, ERBB2, KRT19
6MP:00036317.7TP53, BRCA2, BRCA1, MET, ERBB2, KRT19
7MP:00053817.5TP53, BRCA2, BRCA1, MET, ERBB2, KRT19
8MP:00053807.5TP53, BRCA2, BRCA1, MET, ERBB2, KRT19
9MP:00028737.5TP53, BRCA2, BRCA1, MET, ERBB2, KRT19
10MP:00053857.5VEGFC, TP53, BRCA1, MET, ERBB2, KRT19
11MP:00053787.3TP53, BRCA2, BRCA1, MET, ERBB2, KRT19
12MP:00053877.3VEGFC, SDC1, TP53, BRCA2, BRCA1, MET
13MP:00107717.0SDC1, TP53, BRCA2, BRCA1, ERBB2, KRT19
14MP:00053897.0SDC1, TP53, BRCA2, BRCA1, ERBB2, KRT19
15MP:00053766.8VEGFC, SDC1, TP53, BRCA2, BRCA1, MET
16MP:00020066.7CDH1, SDC1, TP53, BRCA2, BRCA1, MET
17MP:00053796.7SDC1, TP53, BRCA2, BRCA1, MET, ERBB2
18MP:00053846.7SDC1, TP53, BRCA2, BRCA1, MET, ERBB2
19MP:00107686.4VEGFC, SDC1, TP53, BRCA2, BRCA1, MET

Publications for Breast Carcinoma in Situ

About this section

Articles related to Breast Carcinoma in Situ:

(show all 39)
idTitleAuthorsYear
1
Mondor's disease in a patient previously treated for breast carcinoma in situ: a case report. (22595929)
2012
2
Differences in breast carcinoma in situ between menopausal and premenopausal women. (21617240)
2011
3
Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing. (21149333)
2010
4
Pregnancy-related factors and the risk of breast carcinoma in situ and invasive breast cancer among postmenopausal women in the California Teachers Study cohort. (20565829)
2010
5
Might the widespread use of statin drugs explain the increase in prevalence of breast carcinoma in situ? (19896281)
2010
6
Prevalence of breast carcinoma in situ in the United States. (19706857)
2009
7
The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ. (18665169)
2008
8
OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative). (18317962)
2008
9
An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. (17244359)
2007
10
Cigarette smoking and risk of breast carcinoma in situ. (17700252)
2007
11
Oral contraceptive use and risk of breast carcinoma in situ. (18006914)
2007
12
Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women. (17063272)
2007
13
Quality of life for women diagnosed with breast carcinoma in situ. (17050872)
2006
14
Molecular classification of breast carcinoma in situ. (17375183)
2006
15
Oral contraceptive use and risk of breast carcinoma in situ (United States). (17006721)
2006
16
Postmenopausal levels of sex hormones and risk of breast carcinoma in situ: results of a prospective study. (15540225)
2005
17
Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. (15841074)
2005
18
Impact of reproductive factors and lactation on breast carcinoma in situ risk. (15054874)
2004
19
Proliferative lesions of the breast: carcinoma in situ. (15022899)
2003
20
The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. (14659121)
2003
21
Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. (12611452)
2003
22
Oral contraceptives and the risk of ductal breast carcinoma in situ. (14572155)
2003
23
Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. (12670886)
2003
24
Lifetime recreational exercise activity and risk of breast carcinoma in situ. (14601085)
2003
25
DNA content and cell number determination in microdissected samples of breast carcinoma in situ. (12118344)
2002
26
Breast carcinoma in situ: risk factors and screening patterns. (11734598)
2001
27
p53 mutations and expression in breast carcinoma in situ. (10623666)
2000
28
Breast carcinoma in situ in a male. Report of a case diagnosed by nipple discharge cytology. (9622698)
1998
29
Time trend of female breast carcinoma in situ by race and histology in Connecticut, USA. (9071907)
1997
30
Biophenotypes of breast carcinoma in situ defined by image analysis of biological parameters. (8692711)
1996
31
Biological heterogeneity of breast carcinoma in situ. (8651598)
1996
32
Male breast carcinoma in situ. Report of a case diagnosed by nipple discharge cytology alone. (7654052)
1995
33
Breast carcinoma in situ. (20169700)
1992
34
Breast carcinoma-in-situ: an emerging problem in Singapore. (1329232)
1992
35
Ten-year follow-up of breast carcinoma in situ in Connecticut. (1365682)
1992
36
Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. (1677296)
1991
37
Breast carcinoma in situ in 167 women--incidence, mode of presentation, therapy and follow-up. (1657650)
1991
38
Breast carcinoma in situ. (2535929)
1989
39
Breast carcinoma in situ. A retrospective review of 112 cases with a minimum 10 year follow-up. (2990246)
1985

Variations for Breast Carcinoma in Situ

About this section

Expression for genes affiliated with Breast Carcinoma in Situ

About this section
Expression patterns in normal tissues for genes affiliated with Breast Carcinoma in Situ

Search GEO for disease gene expression data for Breast Carcinoma in Situ.

Pathways for genes affiliated with Breast Carcinoma in Situ

About this section

Pathways related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

(show top 50)    (show all 54)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
9.7BRCA1, BRCA2
2
Show member pathways
9.7BRCA2, BRCA1
39.7CDH1, MET
49.7CDH1, MET
59.7CDH1, MET
69.4BRCA1, TP53
79.4BRCA1, TP53
89.4BRCA1, TP53
99.4BRCA1, TP53
109.4TP53, BRCA1
119.4TP53, BRCA1
12
Show member pathways
ATM Signaling Pathway37
9.4TP53, BRCA1
139.4TP53, CDH1
14
Show member pathways
9.4CDH1, MET, VEGFC
159.3KRT19, TP53
169.3MET, SDC1
179.3VEGFC, MET, ERBB2
189.2CDH1, SDC1
199.2MET, ERBB2, CDH1
209.2MET, ERBB2, CDH1
21
Show member pathways
9.2MET, ERBB2, CDH1
22
Show member pathways
9.1TP53, BRCA2, BRCA1
239.1TP53, BRCA2, BRCA1
24
Show member pathways
9.1TP53, BRCA2, BRCA1
25
Show member pathways
9.1TP53, BRCA2, BRCA1
26
Show member pathways
9.1CDH1, MET, TP53
27
Show member pathways
9.0ERBB2, MET, TP53
289.0ERBB2, MET, TP53
29
Show member pathways
9.0TP53, BRCA2, ERBB2
308.9CDH1, ERBB2, TP53
31
Show member pathways
Signal transduction PTEN pathway60
8.9TP53, ERBB2, CDH1
32
Show member pathways
8.8CDH1, ERBB2, MET, VEGFC
33
Show member pathways
8.8VEGFC, MET, ERBB2, CDH1
348.8MET, BRCA1, TP53, VEGFC
358.7VEGFC, TP53, BRCA1, CDH1
36
Show member pathways
8.7ERBB2, MET, TP53, VEGFC
37
Show member pathways
8.7VEGFC, TP53, MET, ERBB2
38
Show member pathways
8.7VEGFC, TP53, MET, ERBB2
398.6CDH1, BRCA1, BRCA2, TP53
408.6TP53, BRCA1, MET, ERBB2
41
Show member pathways
Wnt Signaling Pathway NetPath37
8.6CDH1, TP53, SDC1
428.5ERBB2, BRCA1, BRCA2, TP53
43
Show member pathways
Integrin-mediated cell adhesion37
Focal Adhesion37
8.5VEGFC, SDC1, MET, ERBB2
448.2ERBB2, MET, TP53, SDC1
45
Show member pathways
Development EGFR signaling via PIP360
Development PDGF signaling via MAPK cascades60
Apoptosis and survival Anti apoptotic action of membrane bound ESR160
Signaling of Hepatocyte Growth Factor Receptor37
Development EGFR signaling via small GTPases60
Development Neurotrophin family signaling60
Apoptosis and survival NGF signaling pathway60
Apoptosis and survival Role of CDK5 in neuronal death and survival60
8.2SDC1, TP53, MET, ERBB2
46
Show member pathways
7.9VEGFC, TP53, BRCA2, BRCA1, MET, ERBB2
477.8VEGFC, TP53, BRCA2, MET, ERBB2, CDH1
48
Show member pathways
7.8VEGFC, TP53, BRCA1, MET, ERBB2, CDH1
49
Show member pathways
7.8VEGFC, TP53, BRCA1, MET, ERBB2, CDH1
50
Show member pathways
Signaling Pathways in Glioblastoma37
7.7CDH1, ERBB2, MET, BRCA1, BRCA2, TP53

Compounds for genes affiliated with Breast Carcinoma in Situ

About this section

Compounds related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

(show top 50)    (show all 108)
idCompoundScoreTop Affiliating Genes
1topotecan44 1111.4BRCA1
2crcs449.4MET, TP53, CDH1
3o6-methylguanine449.4BRCA2, TP53, CDH1
4methylmethanesulfonate449.4BRCA2, TP53, BRCA1
55-methylcytosine44 2410.3CDH1, BRCA1, TP53
64-hydroxytamoxifen449.3BRCA1, ERBB2, BRCA2
7leptomycin b44 6110.2CDH1, BRCA1, TP53
8gefitinib44 50 1111.2CDH1, ERBB2, MET
9suberoylanilide hydroxamic acid449.1ERBB2, CDH1, TP53
10oxaliplatin44 50 1111.1TP53, BRCA1, ERBB2
11p003449.1CDH1, BRCA2, KRT19, BRCA1
12folate449.1ERBB2, CDH1, BRCA2, BRCA1
13agar449.1BRCA1, CDH1, ERBB2, MET
14methotrexate50 44 1111.0BRCA2, ERBB2, BRCA1, CDH1
15indole-3-carbinol449.0CDH1, BRCA1, BRCA2, TP53
16bortezomib44 50 1111.0TP53, ERBB2, BRCA1
17phosphotyrosine449.0BRCA1, CDH1, ERBB2, MET
18geldanamycin44 50 61 1111.9MET, TP53, CDH1, ERBB2
19resveratrol44 61 24 1111.9BRCA1, BRCA2, ERBB2, TP53
20irinotecan44 50 1110.9CDH1, TP53, ERBB2
21matrigel448.9CDH1, VEGFC, BRCA2, KRT19, MET
22thymidylate448.8TP53, BRCA1, CDH1, ERBB2
235fluorouracil448.8CDH1, ERBB2, TP53, BRCA1
24heparin44 28 24 1111.8VEGFC, CDH1, ERBB2, BRCA1, MET
25bleomycin44 119.8TP53, BRCA1, BRCA2
26estradiol44 24 1110.7BRCA2, KRT19, VEGFC, BRCA1
27genistein44 28 61 2 24 1113.7BRCA2, CDH1, BRCA1, ERBB2, MET
28oligonucleotide448.7BRCA1, TP53, BRCA2, MET, VEGFC
29proline448.6CDH1, BRCA1, TP53, BRCA2, MET
30ly294002448.6VEGFC, TP53, ERBB2, MET, CDH1
31steroid448.6KRT19, ERBB2, BRCA2, BRCA1, MET
32docetaxel44 50 61 1111.5CDH1, BRCA1, ERBB2, TP53, BRCA2
33doxorubicin44 50 1110.5TP53, MET, CDH1, ERBB2, BRCA1
34etoposide44 50 61 1111.5ERBB2, TP53, CDH1, BRCA1, BRCA2
35tamoxifen44 50 28 1111.5BRCA1, CDH1, BRCA2, TP53, ERBB2
36phosphatidylinositol448.5VEGFC, BRCA2, BRCA1, MET, ERBB2, CDH1
37thymidine44 249.3KRT19, MET, BRCA1, TP53, VEGFC, BRCA2
38p002448.3BRCA2, BRCA1, MET, CDH1, KRT19, ERBB2
39cycloheximide448.1BRCA1, TP53, BRCA2, MET, ERBB2, KRT19
40tyrosine448.0CDH1, VEGFC, BRCA1, MET, KRT19, ERBB2
41paclitaxel44 50 1110.0TP53, BRCA1, ERBB2, CDH1, KRT19, BRCA2
42testosterone44 61 24 1111.0BRCA1, VEGFC, MET, ERBB2, KRT19, CDH1
43retinoic acid44 248.9BRCA2, CDH1, KRT19, MET, BRCA1, TP53
44serine447.8TP53, MET, CDH1, ERBB2, KRT19, BRCA1
45vegf447.7TP53, VEGFC, KRT19, BRCA1, MET, ERBB2
46adriamycin447.7CDH1, KRT19, ERBB2, MET, BRCA1, BRCA2
47cisplatin44 50 61 1110.7ERBB2, MET, BRCA2, TP53, CDH1, KRT19
48paraffin447.4ERBB2, KRT19, MET, BRCA1, CDH1, BRCA2
49progesterone44 28 61 24 1111.4TP53, VEGFC, MET, ERBB2, CDH1, KRT19
50estrogen447.3VEGFC, CDH1, BRCA2, BRCA1, MET, ERBB2

GO Terms for genes affiliated with Breast Carcinoma in Situ

About this section

Cellular components related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1focal adhesionGO:0059258.5SDC1, BRCA1, CDH1
2protein complexGO:0432348.1BRCA1, BRCA2, TP53, SDC1
3cytoplasmGO:0057377.3CDH1, ERBB2, BRCA1, BRCA2, TP53, SDC1

Biological processes related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1cellular response to indole-3-methanolGO:0716819.9CDH1, BRCA1
2response to X-rayGO:0101659.7BRCA2, TP53
3positive regulation of cell cycle arrestGO:0711589.7BRCA1, TP53
4cell agingGO:0075699.7TP53, BRCA2
5response to gamma radiationGO:0103329.6BRCA2, TP53
6intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorGO:0427719.6BRCA2, TP53
7response to estrogenGO:0436279.5BRCA1, KRT19
8positive regulation of epithelial cell proliferationGO:0506799.5ERBB2, VEGFC
9double-strand break repair via homologous recombinationGO:0007249.4BRCA1, BRCA2
10DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:0069789.4BRCA1, BRCA2, TP53
11double-strand break repairGO:0063029.3TP53, BRCA2, BRCA1
12wound healingGO:0420609.1ERBB2, SDC1
13cell proliferationGO:0082839.1ERBB2, MET, TP53
14positive regulation of transcription, DNA-templatedGO:0458938.9TP53, BRCA2, BRCA1, CDH1

Molecular functions related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1protease bindingGO:0020209.5BRCA2, TP53
2glycoprotein bindingGO:0019488.9CDH1, SDC1
3protein phosphatase bindingGO:0199038.5CDH1, ERBB2, MET, TP53
4protein bindingGO:0055156.0VEGFC, SDC1, TP53, BRCA2, BRCA1, MET

Products for genes affiliated with Breast Carcinoma in Situ

About this section
  • Antibodies
  • Proteins
  • Lysates

Sources for Breast Carcinoma in Situ

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
34MeSH
35MESH via Orphanet
36MGI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
58SNOMED-CT via Orphanet
62UMLS
63UMLS via Orphanet